Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL571118 | 0.91 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL24672559 | 0.86 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| Lithium Ion SCHEMBL30694543 | 0.84 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL3498315 | 0.83 | USP2 (0.49) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL225098 | 0.82 | USP2 (0.51) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL78071 | 0.81 | USP2 (0.55) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL571435 | 0.81 | USP2 (0.46) | USP2SMN1; SMN2HPGDEPHX2ATM | |
| SCHEMBL22405855 | 0.81 | HPGD (0.44) | USP2SMN1; SMN2HPGDEPHX2TSHR | |
| SCHEMBL30694561 | 0.81 | SCD5 (0.40) | USP2SMN1; SMN2HPGDEPHX2GPR119 | |
| SCHEMBL1168818 | 0.81 | USP2 (0.50) | USP2SMN1; SMN2HPGDEPHX2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2026-04-07 | — | — | US | disclosed |
| EP-4709720-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4687883-A2 | MODULATORS OF TRPML, THEIR COMPOSITIONS AND METHODS OF USE | Caraway Therapeutics, Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | C4 THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | BIOMEA FUSION INC (US) | 2025-11-20 | — | — | US | disclosed |
| US-12421211-B2 | Heterocyclic compounds | HOFFMANN-LA ROCHE INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | C4 THERAPEUTICS, INC. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | ARVINAS OPERATIONS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| WO-2025098509-A1 | PYRROLIDINE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE THEREOF IN MEDICINE | 康百达（四川）生物医药科技有限公司 | 2025-05-15 | — | — | WO | disclosed |
| EP-2674433-A1 | LIMK2 inhibitors, compositions comprising them and methods of their use | Lexicon Pharmaceuticals, Inc. (US) | 2013-12-18 | — | — | EP | disclosed |
| US-8450332-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2012-12-27 | — | — | US | disclosed |
| US-8193202-B2 | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS, INC. (US) | 2012-06-05 | — | — | US | disclosed |
| CN-101565420-A | LIMK2 inhibitors, compositions comprising them, and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2009-10-28 | — | — | CN | disclosed |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | OXFORD FINANCE LLC, AS COLLATERAL AGENT | 2009-10-22 | — | — | US | disclosed |
| EP-1419155-B1 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2006-11-08 | — | — | EP | disclosed |
| US-20040198756-A1 | Medicaments | SMITHKLINE BEECHAM PLC (GB) | 2004-10-07 | — | — | US | disclosed |
| EP-1419155-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003010138-A2 | PIPERIDINE DERIVATIVES AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368631-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | USP2 44/4885SMN1; SMN2 3369/4885HPGD 3870/4885 |
| US-12421211-B2 | Heterocyclic compounds | F12, C1R, MRPL21 | USP2 4516/4885SMN1; SMN2 3534/4885HPGD 375/4885 |
| US-20120329818-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | USP2 1948/4885SMN1; SMN2 1340/4885HPGD 3269/4885 |
| US-12310975-B2 | Modulators of BCL6 proteolysis and associated methods of use | BCL6, BCL6B, BCL3 | USP2 46/4885SMN1; SMN2 1897/4885HPGD 4107/4885 |
| US-20040198756-A1 | Medicaments | PIGO, PSAP, CD68 | USP2 2709/4885SMN1; SMN2 3564/4885HPGD 328/4885 |
| US-20250382285-A1 | BICYCLIC-SUBSTITUTED GLUTARIMIDE CEREBLON BINDERS | CRBN, STUB1, CUL1 | USP2 44/4885SMN1; SMN2 3369/4885HPGD 3870/4885 |
| US-20250353854-A1 | FUSED PYRIMIDINE COMPOUNDS AS INHIBITORS OF MENIN | MEN1, MLLT1, MSI2 | USP2 3835/4885SMN1; SMN2 2354/4885HPGD 2181/4885 |
| US-12421220-B2 | Bicyclic-substituted glutarimide cereblon binders | CRBN, STUB1, CUL1 | USP2 44/4885SMN1; SMN2 3369/4885HPGD 3870/4885 |
| US-20090264450-A1 | LIMK2 INHIBITORS, COMPOSITIONS COMPRISING THEM, AND METHODS OF THEIR USE | LIMK2, LIMK1, LIMA1 | USP2 1948/4885SMN1; SMN2 1340/4885HPGD 3269/4885 |
| US-12595255-B2 | Heteroaryl-substituted imidazole derivatives | CLIC1, CYP2B6, CYP2D6 | USP2 3774/4885SMN1; SMN2 3383/4885HPGD 3572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.